journal
MENU ▼
Read by QxMD icon Read
search

Journal of Medical Economics

journal
https://www.readbyqxmd.com/read/28782387/cost-analysis-of-leuprorelin-acetate-in-japanese-pre-menopausal-breast-cancer-patients-comparison-between-6-month-and-3-month-depot-formulations
#1
Rei Goto, Akihito Uda, Shinzo Hiroi, Kosuke Iwasaki, Kenta Takashima, Junichi Kurebayashi
AIMS: The aim in this study is to evaluate economic value for leuprorelin acetate 6-month depot compared with leuprorelin acetate 3-month depot in Japanese pre-menopausal breast cancer patients from a societal perspective. METHODS: The cost analysis was conducted by estimating direct and indirect cost, and intangible costs associated with one 6-month injection compared with two 3-month injections. Claims data were used for the analyses of direct and indirect cost and Medical Fee Schedule Table for direct cost...
August 16, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28777020/direct-medical-costs-of-treatment-in-newly-diagnosed-high-grade-glioma-among-commercially-insured-us-patients
#2
Shan Jiang, Kala Hill, Dipen Patel, A Reginald Waldeck, Marc Botteman, Abdalla Aly, Andrew D Norden
AIM: This analysis assessed the direct medical costs of newly-diagnosed, temozolomide (TMZ)-treated glioblastoma (GBM) from the perspective of a US commercial setting. MATERIALS AND METHODS: The analysis included subjects identified from the IMS PharMetrics LifeLink Plus™ claims database from January 1, 2008 to August 31, 2014 who were ≥18 years of age, had ≥1 malignant brain cancer diagnosis, had brain surgery ≤90 days prior to TMZ initiation, had TMZ treatment, and were continuously enrolled for ≥12 months pre-diagnosis and ≥1 month post-diagnosis...
August 16, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28760065/risk-of-major-amputation-or-death-among-patients-with-critical-limb-ischemia-initially-treated-with-endovascular-intervention-surgical-bypass-minor-amputation-or-conservative-management
#3
Ehrin J Armstrong, Michael P Ryan, Erin R Baker, Brad J Martinsen, Harry Kotlarz, Candace Gunnarsson
AIMS: Patients with critical limb ischemia (CLI) have an increased risk of major amputation. The initial treatment approach for CLI may significantly impact the subsequent risk of major amputation or death. The objective of this study was to describe the initial treatment approaches of patients with CLI and the limb outcomes associated with each approach. METHODS: Data from MarketScan Commercial and Medicare Supplemental Databases from January 2006-December 2014 was utilized...
August 16, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28758810/cost-analysis-of-leuprorelin-acetate-in-japanese-prostate-cancer-patients-comparison-between-6-month-and-3-month-depot-formulations
#4
Rei Goto, Akihito Uda, Shinzo Hiroi, Kosuke Iwasaki, Kenta Takashima, Mototsugu Oya
AIMS: This study aimed to evaluate the economic value for leuprorelin acetate 6-month depot compared with leuprorelin acetate 3-month depot from a societal perspective in Japanese prostate cancer patients. METHODS: The cost analysis estimated the reduction in direct and indirect costs as well as intangible costs saved by having one less injection. Claims data were used for the analyses of direct and indirect costs reduction. A discrete choice experiment based on a web-based survey estimated the monetary value of the intangible costs for one injection...
August 16, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28805473/the-impact-of-persistence-with-mirabegron-usage-versus-switching-to-onabotulinumtoxina-on-healthcare-costs-and-resource-utilization-in-patients-with-overactive-bladder-in-the-united-states
#5
Daniel Bin Ng, Robert Espinosa, Scott J Johnson, David Walker, Katherine Gooch
Aims To compare healthcare costs and resource utilization in patients with overactive bladder (OAB) in the United States who switch from mirabegron to onabotulinumtoxinA (onabotA) with those who persist on mirabegron. Materials and methods A retrospective observational claims analysis of the OptumHealth Administrative Claims database conducted between April 1, 2012 and September 30, 2015 used medical and pharmacy claims to identify patients with at least one OAB diagnosis who switched from mirabegron to onabotA (onabotA group) or persisted on mirabegron for at least 180 days (mirabegron persisters)...
August 14, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28803497/exploring-the-potential-value-of-improved-care-for-secondary-hyperparathyroidism-with-a-novel-calcimimetic-therapy
#6
Björn Stollenwerk, Sergio Iannazzo, Kerry Cooper, Vasily Belozeroff
AIMS: This study explored the use of a value-based pricing approach for the new calcimimetic etelcalcetide indicated for the treatment of secondary hyperparathyroidism (SHPT) in patients receiving hemodialysis. It used the US payer perspective and applied the cost-effectiveness framework. Because etelcalcetide is an intravenous therapy that can be titrated for individual patients, and because its utilization is yet to be assessed in real world settings, a range of plausible doses were estimated for etelcalcetide to define a range of prices...
August 14, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28796564/factors-influencing-the-economics-of-biosimilars-in-the-us
#7
Stanton R Mehr, Richard A Brook
No abstract text is available yet for this article.
August 10, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28795868/management-and-cost-analysis-of-cancer-patients-treated-with-g-csf-a-cohort-study-based-on-the-french-national-healthcare-insurance-database
#8
Patrick Tilleul, William Jacot, Corinne Emery, Antoine Lafuma, Julie Gourmelen
OBJECTIVES: To describe the management and costs associated with G-CSF therapy in cancer patients in France. METHODS: We analyzed a representative random population sample from the French national healthcare insurance database, focusing on 1,612 patients with hematological or solid malignancies who were reimbursed in 2013 or 2014 for at least one G-CSF treatment dispensed in a retail pharmacy. Patient characteristics and treatment costs were analyzed according to the type of cancer...
August 10, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28792299/impact-of-medicaid-prescription-copayments-on-use-of-antipsychotics-and-other-medications-in-patients-with-schizophrenia
#9
Jalpa A Doshi, Pengxiang Li, Sunita Desai, Steven C Marcus
OBJECTIVE: To assess the impact of Medicaid prescription copayment policies on antipsychotic and other medication use among patients with schizophrenia. METHOD: The study sample included fee-for-service adult Medicaid patients with schizophrenia. Medicaid claims records from 2003-2005 from 42 states and D.C. were linked with county-level data from the Area Resource File and findings from a state Medicaid policy survey. Patient-level fixed-effects regression models examined the impact of increases in generic copayments and generic/brand copayment differentials on monthly use of antipsychotic (overall and by generic/brand status) and other non-antipsychotic medications...
August 9, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28782449/real-world-economic-burden-of-hematopoietic-cell-transplantation-among-a-large-us-commercially-insured-population-with-hematologic-malignancies
#10
Machaon Bonafede, Akshara Richhariya, Qian Cai, Neil C Josephson, Donna McMorrow, Phillip M Garfin, Miguel-Angel Perales
AIMS: Approximately 20,000 hematopoietic cell transplantation (HCT) procedures are performed in the US annually. This study aims to study the healthcare resource utilization and costs among commercially-insured patients with hematologic malignancies who received autologous HCT (auto-HCT) and allogeneic HCT (allo-HCT) in the US. MATERIALS AND METHODS: Adult patients with hematologic malignancies undergoing auto- or allo-HCT between January 1, 2011 and June 30, 2014 were identified in the Truven Health MarketScan Research Databases...
August 7, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28766370/predictors-for-total-hospital-and-cardiology-cost-claims-among-patients-with-atrial-fibrillation-initiating-dabigatran-or-acenocoumarol-in-the-netherlands
#11
M S Jacobs, M W J van Leent, R G Tieleman, F G A Jansman, Q Cao, M J Postma, M van Hulst
AIMS: The prevalence of atrial fibrillation (AF) has increased over the past years due to aging of the population, and health care costs associated with AF reflect a significant financial burden. The aim of this study was to explore predictors for the real-world AF-related in-hospital costs in patients that recently initiated anticoagulation with acenocoumarol or dabigatran. METHODS: Predictors for claimed total hospital care costs and cardiology costs in AF patients were explored by using hospital financial claims data from propensity score matched patient groups in a large Dutch community hospital...
August 2, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28762848/healthcare-resource-utilization-and-costs-for-patients-with-pulmonary-arterial-hypertension-real-world-documentation-of-functional-class
#12
Robert Dufour, Janis Pruett, Nan Hu, Cassandra Lickert, Stephen Stemkowski, Yuen Tsang, Daniel Lane, William Drake
BACKGROUND AND AIMS: Pulmonary arterial hypertension (PAH) is a rare medical disease in which patients experience increased pulmonary vascular resistance (PVR) and pulmonary arterial pressure that can result in remodeling of the pulmonary vasculature and heart and eventually lead to right heart failure and death. As PAH progresses, patients become unable to perform even routine daily tasks without severe shortness of breath (dyspnea), fatigue, dizziness, and fainting (syncope). Treatment strategies largely depend on assessment of an individual patient's WHO Functional Class...
August 1, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28762843/cost-effectiveness-of-3-month-paliperidone-therapy-for-chronic-schizophrenia-in-the-netherlands
#13
Thomas R Einarson, Basil G Bereza, Fadi Tedouri, Kristel Van Impe, Tom R Denee, Pieter J T Dries
BACKGROUND: A new depot formulation of paliperidone has been developed that provides effective treatment for schizophrenia for three months (PP3M). It has been tested in phase-3 trials, but no data on its cost-effectiveness have been published. PURPOSE: To determine the cost-effectiveness of PP3M compared with once-monthly paliperidone (PP1M), haloperidol long-acting therapy (HAL-LAT), risperidone microspheres (RIS-LAT), and oral olanzapine (oral-OLZ) for treating chronic schizophrenia in The Netherlands...
August 1, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28760063/incremental-economic-burden-associated-with-major-bleeding-among-atrial-fibrillation-patients-treated-with-factor-xa-inhibitors
#14
Steven Deitelzweig, W Richey Neuman, Melissa Lingohr-Smith, Brandy Menges, Jay Lin
OBJECTIVE: To evaluate healthcare resource use and costs incurred during, as well as following hospitalization for major bleeding (MB), among atrial fibrillation (AF) patients treated with factor Xa inhibitors Methods: Patients with an AF diagnosis and MB hospitalization (index event) were identified from the MarketScan Commercial and Medicare databases (1/1/2011-12/31/2014). Patients were required to have ≥1 prescription for rivaroxaban or apixaban within 3 months prior to MB hospitalization...
August 1, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28760056/cost-per-additional-responder-for-ixekizumab-and-other-fda-approved-biologics-in-moderate-to-severe-plaque-psoriasis
#15
Sarah Al Sawah, Shonda A Foster, Russel Burge, David Amato, Alexander Schacht, Baojin Zhu, Susanne Hartz, Craig Leonardi
BACKGROUND: Evidence of the cost-efficacy of ixekizumab for the treatment of moderate-to-severe plaque psoriasis (PsO) in the United States (US) is limited. OBJECTIVE: To estimate the number needed to treat (NNT) and monthly cost of achieving one additional Psoriasis Area and Severity Index (PASI) 75, 90, and 100 responder for ixekizumab and other Food and Drug Administration (FDA)-approved biologics in PsO. METHODS: A network meta-analysis estimated the probability of achieving PASI 75, 90, or 100 response during induction for each biologic...
August 1, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28760047/demographics-treatment-patterns-and-healthcare-utilization-and-cost-of-repository-corticotropin-injection-in-patients-with-systemic-lupus-erythematosus-or-rheumatoid-arthritis
#16
Bingcao Wu, Gaurav Deshpande, Tao Gu, Breanna Popelar, Michael Philbin, George J Wan
OBJECTIVE: To evaluate healthcare resource utilization (HRU) and costs among patients who initiated repository corticotropin injection (RCI; H.P. Acthar® Gel) treatment for rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). METHODS: Patients aged ≥18 years with ≥2 diagnoses for either RA or SLE between 07/01/2006 and 04/30/2015 were identified in the HealthCore Integrated Research Database. Index RCI date was earliest date of a medical or pharmacy claim for RCI after diagnosis...
August 1, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28758857/brain-metastases-in-non-small-cell-lung-cancer-patients-on-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors-symptom-and-economic-burden
#17
Ancilla W Fernandes, Bingcao Wu, Ralph M Turner
OBJECTIVE: This study describes the symptom and economic burden associated with brain metastases (BM) in patients with non-small cell lung cancer (NSCLC) receiving epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs). METHODS: This retrospective study included adults with ≥2 medical claims, within 90 days, for lung cancer and ≥1 administration of EGFR-TKIs. Based on ICD-9 codes, patients were stratified into cohorts by type of metastases (BM, other metastases [OM], or no metastases [NM]), and by when the metastasis diagnosis occurred (synchronous or asynchronous)...
July 31, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28703659/cost-effectiveness-analysis-of-ocrelizumab-versus-subcutaneous-interferon-beta-1a-for-the-treatment-of-relapsing-multiple-sclerosis
#18
Hongbo Yang, Emilie Duchesneau, Rebekah Foster, Annie Guerin, Esprit Ma, Nina P Thomas
AIM: To conduct a cost-effectiveness analysis to compare ocrelizumab vs subcutaneous (SC) interferon beta-1a for the treatment of relapsing multiple sclerosis (RMS). METHODS: A Markov cohort model with a 20-year horizon was developed to compare ocrelizumab with SC interferon beta-1a from a US payer perspective. A cohort of patients with relapsing-remitting MS (RRMS) and Expanded Disability Status Scale (EDSS) scores of 0-6, who initiated treatment with ocrelizumab or SC interferon beta-1a, were entered into the model...
July 31, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28685629/examining-the-association-of-smoking-with-work-productivity-and-associated-costs-in-japan
#19
Kiyomi Suwa, Natalia M Flores, Reiko Yoshikawa, Rei Goto, Jeffrey Vietri, Ataru Igarashi
AIMS: Smoking is associated with significant health and economic burden globally, including an increased risk of many leading causes of mortality and significant impairments in work productivity. This burden is attenuated by successful tobacco cessation, including reduced risk of disease and improved productivity. The current study aimed to show the benefits of smoking cessation for workplace productivity and decreased costs associated with loss of work impairment. MATERIALS AND METHODS: The data source was the 2011 Japan National Health and Wellness Survey (n = 30,000)...
July 31, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28745579/re-a-dynamic-approach-for-outpatient-scheduling
#20
Cheryl Lim, Rahul Chodhari
No abstract text is available yet for this article.
July 26, 2017: Journal of Medical Economics
journal
journal
34457
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"